Severe insulin-deficient type 2 diabetes patients
BMEABiomea FusionCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for BMF-219 (icovamenib) + GLP-1-based therapy in Severe insulin-deficient type 2 diabetes patients. The expected timing is based on the latest available company guidance and may change.
COVALENT-211 study. 10/6/25- Initiate study in Q4 2025. 11/04/25:- COVALENT-211 Ph2b initiation expected Q4 2025; first patient in anticipated Q1 2026. 01/12/26:- COVALENT-211 Ph2b FPI expected Q1 2026; 26-week HbA1c primary endpoint data expected Q4 2026. 03/24/26:- COVALENT-211 Phase II trial initiated; 26-week primary endpoint topline data anticipated in Q4 2026. 03/31/26:- First patient dosed in COVALENT-211; enrolling in Q2 2026; topline 26-week data expected Q4 2026. 05/11/26:- COVALENT-211 enrollment ongoing; topline 26-week data remains expected Q4 2026. 08/05/26:- COVALENT-211 enrollment ongoing; 26-week data now expected Q1 2027.
Verification
Confirm timing and program details against the company announcement or filing.